000590

7.740.77%

TUS-PHARMA released its first-quarter performance, with a net loss attributable to the parent company of 16.2562 million yuan

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, TUS-PHARMA (000590.SZ) released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 65.2203 million yuan, a year-on-year decrease of 15.40%. The net loss attributable to shareholders of the listed company was 16.2562 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 17.0899 million yuan

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.